HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Peripheral administration of the melanocortin-4 receptor antagonist NBI-12i ameliorates uremia-associated cachexia in mice.

Abstract
We have recently shown that genetic or pharmacological blockade of the melanocortin-4 receptor (MC4-R) attenuates uremia-associated cachexia. However, the potential clinical utility of this approach has been limited by the need to deliver a peptide MC4-R antagonist into the ventricles of the brain. NBI-12i is a recently developed small molecule MC4-R antagonist, with high affinity and selectivity that penetrates the central nervous system after peripheral administration. We tested whether NBI-12i would also be effective in attenuating uremia-associated cachexia in a mouse model. Intraperitoneal administration of NBI-12i stimulated food intake and weight gain in uremic mice. Furthermore, NBI-12i-treated uremic mice gained lean body mass, fat mass, and had a lower basal metabolic rate compared to vehicle-treated and diet-supplemented uremic mice, which lost both lean body mass and fat mass and had an increase in basal metabolic rate. We found that NBI-12i normalizes the expression of uncoupling protein, which is normally upregulated in uremic mice, and we speculate that this may contribute to the drug's protective effect. These data underscore the importance of melanocortin signaling in the pathogenesis of uremia-associated cachexia and demonstrate the potential of peripheral administration of MC4-R antagonists as a novel therapeutic approach.
AuthorsWai W Cheung, Huey-Ju Kuo, Stacy Markison, Chen Chen, Alan C Foster, Daniel L Marks, Robert H Mak
JournalJournal of the American Society of Nephrology : JASN (J Am Soc Nephrol) Vol. 18 Issue 9 Pg. 2517-24 (Sep 2007) ISSN: 1046-6673 [Print] United States
PMID17687077 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
Chemical References
  • Cytokines
  • Inflammation Mediators
  • Ion Channels
  • Mitochondrial Proteins
  • NBI-12i
  • Piperazines
  • RNA, Messenger
  • Receptor, Melanocortin, Type 4
  • Uncoupling Protein 1
  • Uncoupling Protein 3
Topics
  • Animals
  • Basal Metabolism (drug effects)
  • Cachexia (etiology, metabolism, physiopathology)
  • Cytokines (blood)
  • Eating (drug effects)
  • Inflammation Mediators (blood)
  • Ion Channels (genetics, metabolism)
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mitochondrial Proteins (genetics, metabolism)
  • Nephrectomy
  • Piperazines (administration & dosage, pharmacology)
  • RNA, Messenger (metabolism)
  • Receptor, Melanocortin, Type 4 (antagonists & inhibitors)
  • Uncoupling Protein 1
  • Uncoupling Protein 3
  • Uremia (complications)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: